Monoclonal Antibodies Market Size to Gain USD 494.55 BN by 2030

According to Nova one advisor's recent analyses the global Monoclonal Antibodies market size is expected to hit USD 494.55 billion by 2030 from at USD 210.07 billion in 2022 and is expanding growth at a noteworthy CAGR of 11.32% from 2022 to 2030.

Get the Free Sample Copy of Report@


Key Takeaways:

  • By source type, the U.S. Monoclonal Antibodies market was valued at USD 70.4 Billion in 2021 and expected to witness growth at a CAGR of 10.3% from 2022 to 2030.
  • By source type, the human mAbs segment held the largest share of 54.07% in 2021 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies
  • In vitro production type held a dominating share of 78.45% in 2021 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities
  • The oncology segment dominated the market in 2021 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies
  • Hospitals accounted for the largest share of the end-use segment in 2021 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics
  • North America accounted for 46.2% of the market value in 2021 due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and local presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others
  • The Asia Pacific is projected to witness the highest growth rate in the forecast period due to the availability of a large patient pool for cancer treatment and expanding the scope of clinical research prospects for mAbs.

Report Scope of the Monoclonal Antibodies Market

Report Coverage


Market Size

US$ 494.55 Billion by 2030

Growth Rate

CAGR of 11.32% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

 Source type, production type, application, end-use and Region,

Immediate Delivery Available | Buy this Premium Research Report@

Rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and others are increasing the demand for biologics, which is anticipated to serve as a key factor driving the monoclonal antibodies (mAbs) market. Similarly, increasing applications of mAb therapies for targeted therapies and rising awareness about such therapies amongst patients and physicians is expected to significantly contribute toward the market growth.

Furthermore, the COVID-19 pandemic has increased the market expansion prospects by fueling the development of several mAbs directed against the SARS-CoV-2 virus. As mAbs represent a promising alternative for mitigation of COVID-19 due to their safety and effectiveness, several such antibodies have attained emergency use authorizations (EUA) from the U.S. FDA. For instance, in February 2022, the U.S. FDA granted a EUA to Eli Lilly’s bebtelovimab for treatment of COVID-19 patients that are at risk of developing severe disease or who may need hospitalization. In addition, the U.S. Department of Health and Human Services announced the distribution of at least 600,000 free bebtelovimab courses, along with an optional purchase of 500,000 additional doses in the future, thus creating new opportunities for growth of mAbs/Key advantages offered by mAb therapies over previous therapies in terms of specificity, effectiveness, and ease of delivery have led to numerous new product launches and approvals in this domain. Over 100 mAb products have been approved by the U.S. FDA and the scope of therapeutic mAb applications is expected to grow further due to the development of antibody fragments, antibody derivatives, and bispecific antibodies, that offer advanced treatment options.

The market is also favored by the strategic initiatives undertaken by key players for the development and marketing of mAb products. For instance, in October 2021, T-Cure Bioscience, Inc. collaborated with Atlas Antibodies AB for the production and supply of CT83 mAbs. Similarly, in January 2022, Ono Pharmaceutical Co., Ltd. and Neurimmune AG collaborated on the creation of mAb drugs against new therapeutic targets for neurodegenerative diseases. Such initiatives are expected to open new growth opportunities and positively affect market growth.

However, high costs associated with the development of mAbs and the resultant increase in prices for mAb therapeutics can impede market growth in the near future. For instance, COVID-19 treatment mAbs such as Regeneron’s REGEN-COV (casirivimab and imdevimab), and GlaxoSmithKline & Vir Biotechnology’s sotrovimab cost around USD 1,250 and USD 2,100 per infusion, respectively. Such high drug prices can limit the access to mAb therapies for the large patient populations in developing countries and restrict mAbs adoption.

Related Reports

Regional Insights

North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research prospects, among other factors. Moreover, increasing government expenditure for cancer research and the presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others, are expected to boost the market growth.

Asia Pacific region is projected to exhibit the fastest growth rate in the forecast period due to the increasing disposable income, availability of a large patient pool for mAb cancer therapeutics, and rising focus on healthcare. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for mAbs. 

Ask here for more customization study@

Some of the prominent players in the Monoclonal Antibodies Market include:

  • Novartis AG
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Merck & Co., Inc.
  • Daiichi Sankyo Company, Limited
  • Abbott Laboratories
  • AstraZeneca plc
  • Eli Lilly And Company
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Bristol Myers Squibb
  • F. Hoffman-La Roche Ltd.
  • Viatris Inc.
  • Biogen Inc.
  • Thermo Fisher Scientific, Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Merck KGaA

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Monoclonal Antibodies market

  • Source type
    • Murine
    • Chimeric
    • Humanized
    • Human
  • Production Type
    • In Vivo
    • In Vitro
  • Application
    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases
    • Neurological Diseases
    • Others
  • End-use
    • Hospitals
    • Specialty Centers
    • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Report is Ready | For Purchase Inquiry@

You can place an order or ask any questions, please feel free to| +1 9197 992 333






Back to news